Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Krane
Stephen M
SM
Harvard Medical School and Massachusetts General Hospital, Center for Immunology and Inflammatory Diseases, Department of Medicine, Boston, MA 02129, USA. krane.stephen@mgh.harvard.edu
D000284:Administration, Oral; D000328:Adult; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D010001:Osteitis Deformans / Q000188:drug therapy*; D000068296:Risedronic Acid; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000068296:Risedronic Acid; D012968:Etidronic Acid